TY - JOUR
T1 - Orexin-A in the human brain and tumor tissues of ganglioneuroblastoma and neuroblastoma
AU - Arihara, Zenei
AU - Takahashi, Kazuhiro
AU - Murakami, Osamu
AU - Totsune, Kazuhito
AU - Sone, Masahiko
AU - Satoh, Fumitoshi
AU - Ito, Sadayoshi
AU - Hayashi, Yutaka
AU - Sasano, Hironobu
AU - Mouri, Toraichi
N1 - Funding Information:
The authors are grateful to Ms Kikuchi for her technical assistance. This study has been supported in part by a Research Grant from the Takeda Science Foundation (to K. To.), by a Research Grant for the Renal Anemia Research (to K. To.), by the Mochida Memorial Foundation for Medical and Pharmaceutical Research (to K. Ta.), and a Grant-in-Aid for Scientific Research on Priority Areas (A) (to K. Ta.) from the Ministry of Education, Science, Sports, and Culture, Japan.
PY - 2000/4
Y1 - 2000/4
N2 - Regional distribution of orexin-A-like immunoreactivity in the human brain and pituitary, and the presence of orexin-A-like immunoreactivity in the tumor tissues of pheochromocytomas, ganglioneuroblastomas and neuroblastomas were studied by radioimmunoassay. Expression of orexin mRNA was studied by reverse transcriptase polymerase chain reaction (PCR) method. Orexin-A-like immunoreactivity was detected in every region of human brain, but not in the pituitary. The highest concentration of orexin-A-like immunoreactivity in the human brain was found in hypothalamus (17.8 ± 4.3 pmol/g wet weight, mean ± SEM, n = 7), followed by thalamus, medulla oblongata, and pons. Orexin-A-like immunoreactivity was detected in the tumor tissues of ganglioneuroblastoma and neuroblastoma, but not in the tumor tissues of pheochromocytoma. Reverse phase high performance liquid chromatographic analyses of the orexin-A-like immunoreactivity in the human brain extracts and neuroblastoma extracts showed a single immunoreactive peak, which was eluted in an identical position to synthetic human orexin-A. Orexin mRNA was expressed in the hypothalamus and in the tumor tissues of ganglioneuroblastoma and neuroblastoma. These findings suggest that orexin-A is produced in the hypothalamus and transported to various brain regions via axons. In addition, this study has shown for the first time the production of orexin-A by ganglioneuroblastomas and neuroblastomas. Copyright (C) 2000 Elsevier Science Inc.
AB - Regional distribution of orexin-A-like immunoreactivity in the human brain and pituitary, and the presence of orexin-A-like immunoreactivity in the tumor tissues of pheochromocytomas, ganglioneuroblastomas and neuroblastomas were studied by radioimmunoassay. Expression of orexin mRNA was studied by reverse transcriptase polymerase chain reaction (PCR) method. Orexin-A-like immunoreactivity was detected in every region of human brain, but not in the pituitary. The highest concentration of orexin-A-like immunoreactivity in the human brain was found in hypothalamus (17.8 ± 4.3 pmol/g wet weight, mean ± SEM, n = 7), followed by thalamus, medulla oblongata, and pons. Orexin-A-like immunoreactivity was detected in the tumor tissues of ganglioneuroblastoma and neuroblastoma, but not in the tumor tissues of pheochromocytoma. Reverse phase high performance liquid chromatographic analyses of the orexin-A-like immunoreactivity in the human brain extracts and neuroblastoma extracts showed a single immunoreactive peak, which was eluted in an identical position to synthetic human orexin-A. Orexin mRNA was expressed in the hypothalamus and in the tumor tissues of ganglioneuroblastoma and neuroblastoma. These findings suggest that orexin-A is produced in the hypothalamus and transported to various brain regions via axons. In addition, this study has shown for the first time the production of orexin-A by ganglioneuroblastomas and neuroblastomas. Copyright (C) 2000 Elsevier Science Inc.
KW - Ganglioneuroblastoma
KW - Human brain
KW - Hypocretin
KW - Neuroblastoma
KW - Orexin
KW - PCR
KW - Radioimmunoassay
UR - http://www.scopus.com/inward/record.url?scp=0034060774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034060774&partnerID=8YFLogxK
U2 - 10.1016/S0196-9781(00)00184-4
DO - 10.1016/S0196-9781(00)00184-4
M3 - Article
C2 - 10822113
AN - SCOPUS:0034060774
SN - 0196-9781
VL - 21
SP - 565
EP - 570
JO - Peptides
JF - Peptides
IS - 4
ER -